Clinical characteristics of patients by B2M immunohistochemistry
| . | Total cohort . | Β2M positive . | Β2M negative . | P . |
|---|---|---|---|---|
| Median age (range), y | 32 (11-85) | 47 (11-85) | 30 (13-76) | <.0001* |
| Males, n (%) | 80/145 (55) | 35/52 (67) | 45/93 (48) | .037* |
| Histology | ||||
| NS, n (%) | 105/145 (72) | 25/52 (48) | 80/93 (86) | <.0001* |
| MC, n (%) | 30/145 (21) | 23/52 (44) | 7/93 (8) | <.0001* |
| Other or | ||||
| intermediate, n (%) | 9/145 (6) | 3/52 (6) | 6/93 (6) | 1 |
| Stage | ||||
| I/II, n (%) | 84/129 (66) | 20/45 (44) | 63/85 (74) | .0011* |
| III/IV, n (%) | 47/129 (36) | 25/45 (56) | 22/85 (26) | .0011* |
| B symptoms, n (%) | 47/113 (41) | 19/39 (49) | 28/74 (38) | .32 |
| Bulk disease, n (%) | 17/127 (13) | 2/47 (4) | 15/80 (19) | .029 |
| . | Total cohort . | Β2M positive . | Β2M negative . | P . |
|---|---|---|---|---|
| Median age (range), y | 32 (11-85) | 47 (11-85) | 30 (13-76) | <.0001* |
| Males, n (%) | 80/145 (55) | 35/52 (67) | 45/93 (48) | .037* |
| Histology | ||||
| NS, n (%) | 105/145 (72) | 25/52 (48) | 80/93 (86) | <.0001* |
| MC, n (%) | 30/145 (21) | 23/52 (44) | 7/93 (8) | <.0001* |
| Other or | ||||
| intermediate, n (%) | 9/145 (6) | 3/52 (6) | 6/93 (6) | 1 |
| Stage | ||||
| I/II, n (%) | 84/129 (66) | 20/45 (44) | 63/85 (74) | .0011* |
| III/IV, n (%) | 47/129 (36) | 25/45 (56) | 22/85 (26) | .0011* |
| B symptoms, n (%) | 47/113 (41) | 19/39 (49) | 28/74 (38) | .32 |
| Bulk disease, n (%) | 17/127 (13) | 2/47 (4) | 15/80 (19) | .029 |
The total cohort included 145 patients; 52 B2M positive and 93 B2M negative.
Statistically significant difference according to a P value of <.05.